A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PALI SEC filings page.
Palisade Bio, Inc. (PALI) reported $500K in revenue over the twelve months to Sep 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Palisade remains a development-stage business whose FY2025 balance-sheet expansion came from financing while operations continued consuming cash.
FY2025 financing cash flow was$134.4M against operating cash flow of-$10.8M . Assets expanded1134.8% , indicating that the enlarged balance sheet reflects funding activity more than internally generated operating scale.
The cash-conversion picture is not a mirror of the reported loss: FY2025 net loss was
FY2025 liabilities were only
Financial Health Signals
We do not publish a peer-relative financial health score for Palisade Bio, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Palisade Bio, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Palisade Bio, Inc. reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Palisade Bio, Inc. reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Palisade Bio, Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 100.0%.
Palisade Bio, Inc.'s EBITDA was -$15.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Palisade Bio, Inc. reported a net loss of $14.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Palisade Bio, Inc. earned -$0.07 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Palisade Bio, Inc. held $113.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Palisade Bio, Inc.'s quarterly ROE was -13.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 76.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Palisade Bio, Inc. invested $12.0M in research and development in Q3 2026. This represents an increase of 760.8% from the same quarter a year earlier. Against the prior quarter it is up 62.2%.
Not reported for Q3 2026.
Not reported for Q3 2026.
PALI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $500Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| R&D Expenses | $12.0M+760.8% | $7.4M+341.8% | $6.4M+573.4% | $6.2M | $1.4M-91.3% | $1.7M-36.3% | $950K-57.1% | N/A |
| SG&A Expenses | $5.1M+235.1% | $4.8M+310.8% | $4.4M+219.9% | $3.8M+193.4% | $1.5M+4.9% | $1.2M-26.2% | $1.4M-6.8% | $1.3M-16.7% |
| Operating Income | -$15.7Mn/m | -$11.7Mn/m | -$10.7Mn/m | -$10.0Mn/m | -$2.9Mn/m | -$2.8Mn/m | -$2.3Mn/m | -$3.4Mn/m |
| EBITDA | -$15.7Mn/m | -$11.7Mn/m | -$10.7Mn/m | -$10.0Mn/m | -$2.9Mn/m | -$2.8Mn/m | -$2.3Mn/m | -$3.4Mn/m |
| Interest Expense | $0-100.0% | $0-100.0% | $1K0.0% | $2K-33.3% | $5K-16.7% | $2K0.0% | $1K0.0% | $3K-25.0% |
| Net Income | -$14.6Mn/m | -$10.6Mn/m | -$9.6Mn/m | -$8.9Mn/m | -$2.9Mn/m | -$2.8Mn/m | -$2.2Mn/m | -$3.3Mn/m |
| EPS (Basic) | -$0.07 | -$0.05 | -$0.05 | N/A | -$0.38 | -$0.58 | -$0.47 | -$0.69 |
| EPS (Diluted) | -$0.07 | -$0.05 | -$0.05 | N/A | -$0.38 | -$0.58 | -$0.47 | -$0.69 |
| Diluted Shares (Avg) | 212M | 211M | 210M | N/A | 7M | 5M | 5M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
PALI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $118.5M+1600.1% | $127.3M+1809.6% | $133.3M+1527.8% | $134.3M+1134.8% | $7.0M-25.3% | $6.7M-48.2% | $8.2M-35.3% | $10.9M-22.6% |
| Current Assets | $117.5M+1620.5% | $127.3M+1873.9% | $133.2M+1589.4% | $134.2M+1179.0% | $6.8M-23.0% | $6.4M-47.6% | $7.9M-34.3% | $10.5M-21.3% |
| Cash & Equivalents | $113.6M+2073.6% | $125.2M+2210.7% | $132.6M+1734.4% | $133.4M+1258.2% | $5.2M-35.0% | $5.4M-52.3% | $7.2M-35.9% | $9.8M-21.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | N/A | $500Kn/m | N/A | $0n/m | N/A | $0 | N/A | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $6.1M+62.3% | $5.6M+37.6% | $6.0M+108.2% | $5.0M+46.5% | $3.8M+37.9% | $4.0M+38.5% | $2.9M+10.5% | $3.4M+23.7% |
| Current Liabilities | $5.8M+67.5% | $5.2M+32.1% | $5.6M+102.4% | $4.6M+43.3% | $3.5M+29.7% | $4.0M+40.0% | $2.8M+12.6% | $3.2M+25.1% |
| Non-Current Liabilities | $279K-1.4% | $321K+316.9% | $333K+306.1% | $328K+115.8% | $283K+502.1% | $77K-10.5% | $82K-32.2% | $152K-0.7% |
| Total Equity | $112.4M+3400.6% | $121.7M+4546.9% | $127.4M+2289.1% | $129.4M+1626.9% | $3.2M-51.4% | $2.6M-73.7% | $5.3M-47.0% | $7.5M-33.8% |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | $141.0Mn/m | $138.2Mn/m | $135.9M+11.9% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
PALI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.8Mn/m | -$7.6Mn/m | -$3.9Mn/m | -$3.1Mn/m | -$3.6Mn/m | -$1.8Mn/m | -$2.3Mn/m | -$2.4Mn/m |
| Depreciation & Amortization | $0-100.0% | $0-100.0% | $0-100.0% | $0n/m | $1K0.0% | $1K0.0% | $1K0.0% | $0n/m |
| Stock-Based Compensation | $5.1M+5842.4% | $4.8M+7858.3% | $4.3M+6127.5% | N/A | $85K-7.6% | $60K-83.2% | $69K-41.5% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$2.4Mn/m |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Financing Cash Flow | $200K-94.1% | $147K+3575.0% | $3.1Mn/m | $131.3M+3055.5% | $3.4Mn/m | $4K-99.9% | -$258K-112.7% | $4.2Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PALI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -2339.6% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -2114.8% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -13.0%+76.3pp | -8.7%+97.6pp | -7.5%+34.3pp | -6.9%+37.7pp | -89.3%-36.5pp | -106.3%-65.3pp | -41.8%-6.8pp | -44.6%-18.4pp |
| Return on Assets | -12.3%+28.8pp | -8.3%+33.5pp | -7.2%+20.0pp | -6.6%+24.1pp | -41.1%-3.8pp | -41.8%-10.1pp | -27.2%+0.7pp | -30.7%-9.6pp |
| Current Ratio | 20.16+18.2x | 24.26+22.6x | 23.71+20.9x | 28.95+25.7x | 1.96-1.3x | 1.62-2.7x | 2.84-2.0x | 3.24-1.9x |
| Liabilities-to-Equity | 0.05-1.1x | 0.05-1.5x | 0.05-0.5x | 0.04-0.4x | 1.17+0.8x | 1.54+1.3x | 0.54+0.3x | 0.45+0.2x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Palisade Bio, Inc. PALI | FY2025 | $0 | -$16.8M | N/A | $150.7M | — |
| Oramed Pharmaceuticals Inc. ORMP | FY2025 | $2.0M | $64.0M | N/A | $155.2M | 53/100 |
| InflaRx N.V. IFRX | FY2025 | $34K | -$53.6M | N/A | $153.3M | — |
| ProQR Therapeutics N.V. PRQR | FY2025 | $18.7M | -$49.5M | N/A | $147.0M | 74/100 |
| BridgeBio Oncology Therapeutics, Inc. BBOT | FY2025 | N/A | -$134.0M | N/A | $145.3M | — |
| Sutro Biopharma, Inc. STRO | FY2025 | $102.5M | -$191.1M | N/A | $142.8M | 42/100 |
Where Palisade Bio, Inc. Ranks
Frequently Asked Questions
Palisade Bio, Inc. (PALI) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Palisade Bio, Inc. (PALI) reported a net loss of $43.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $16.8M.
Palisade Bio, Inc. (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Palisade Bio, Inc. (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Palisade Bio, Inc. (PALI) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Palisade Bio, Inc. (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.
Palisade Bio, Inc. (PALI) invested $10.2M in research and development during fiscal year 2025.
Palisade Bio, Inc. (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.
Palisade Bio, Inc. (PALI) had a liabilities-to-equity ratio of 0.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Palisade Bio, Inc. (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Palisade Bio, Inc. (PALI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $150.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Palisade Bio, Inc. (PALI) trades at 301x sales, its market capitalization divided by $500K revenue, trailing 12 months to September 30, 2026. The market capitalization is $150.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Palisade Bio, Inc. (PALI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Palisade Bio, Inc. (PALI) reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Palisade Bio, Inc. (PALI) reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.